Investor Presentation Full Year 2021
115
Investor presentation Full year 2021
North America Operations at a glance.
NAO
WA
30
56
56
48
20
10
0
2019
2030
Diabetes trend in population
Diabetes market by value and
Novo Nordisk market share
Million
DKK
billion
70
13%
600
60
18%
50
40
Novo Nordisk reported sales
Full year 2021
Sales
(mDKK)
Growth²
80%
Total GLP-13
37,491
25%
Long-acting insulin4
6,990
(15%)
60%
Premix insulin5
691
6%
400
GLP-1
36%¹
Fast-acting insulin
6,784
(6%)
40%
Human insulin
1,599
8%
63
Total insulin
16,064
(9%)
Insulin
2%1
200
Other Diabetes care?
950
(10%)
20%
Diabetes care
54,505
12%
12%1
OAD
Obesity care8
5,283
57%
0
0%
Nov
2045
2016
Population with diabetes
Diabetes growth rate
GLP-1 MS
Insulin MS
Nov
2021
OAD MS
Diabetes & Obesity
59,788
15%
care
Biopharm⁹
Total
7,475
6%
67,263
14%
International Diabetes Federation: Diabetes Atlas 1th Edition
2000 and Diabetes Atlas 9th Edition 2019
1 CAGR calculated for 5-year period
Competitor insulin value market shares, as of Nov 2021: Novo Nordisk 42%,
Eli Lilly 30% and Sanofi 27%; Competitor GLP-1 value market shares, as of
Nov 2021: Novo Nordisk 52%, Eli Lilly 45% and AstraZeneca 4%
OAD: Oral anti-diabetic; MS: Market Share; Source: IQVIA MAT, Nov 2021
value figures
2 At constant exchange rates; 3 Comprises Victoza®, OzempicⓇ, and RybelsusⓇ;
4 Comprises Tresiba®, XultophyⓇ and Levemir®; 5 Comprises NovoMixⓇ;
6 Comprises FiaspⓇ and NovoRapid®; 7 Comprises Novo NormⓇ and needles; 8
Comprises SaxendaⓇ and Wegovy ® 9 Comprises primarily NovoSeven®,
NovoEight® Esperoct®, NovoThirteenⓇ, Refixia®, Norditropin®, VagifemⓇ and
Activelle®View entire presentation